Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Chief Commercial Officer | March 15, 2022 | March 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Insight Molecular Diagnostics Inc.
Report date March 15, 2022 · Filed March 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2032-03-15 | Direct | 87,500 |
Reported balance
After 2022-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-15 · Grant · Acquired 87,500 · Balance 87,500 F1: 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2032-03-15 | Direct | 87,500 |
Reported balance
After 2022-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-15 · Grant · Acquired 87,500 · Balance 87,500 F2: Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
F2: Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2022 Filed Mar 17, 2022 21:24 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 87,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-007201 · ownership.xml · derivative · entry 2 Sundar Padmavathi · CIK 0001778709 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2032-03-15 F2 · derivative.exercise_date: Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:24 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 87,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-007201 · ownership.xml · derivative · entry 1 Sundar Padmavathi · CIK 0001778709 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2032-03-15 F1 · derivative.exercise_date: 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 16:35 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantEmployee Stock Option (right to buy) · Derivative | 255,000 | $5.34 Strike: $5.34 | $1,361,700.00 |
DisclosureSEC source: 0001493152-21-005107 · ownership.xml · derivative · entry 1 Sundar Padmavathi · CIK 0001778709 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2031-02-24 F1 · derivative.exercise_date: Vesting: Twenty-five percent of the options will vest and thereby become exercisable upon completion of one year of service from the date of grant, and the balance of the options will vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, subject to her continued service as an employee on the applicable vesting date. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 06:25 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock | 4,177 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-023595 · ownership.xml · nonDerivative · entry 1 Sundar Padmavathi · CIK 0001778709 · SVP, Marketing & Market Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,177 F1 · price: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:52 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to purchase common stock · Derivative | 255,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001493152-20-002153 · ownership.xml · derivative · entry 1 Sundar Padma · CIK 0001778709 · SVP, Marketing & Market Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on February 10, 2020 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date.(1) Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.